Related Experiment Video
Updated: Jul 5, 2026

High Throughput, Real-time, Dual-readout Testing of Intracellular Antimicrobial Activity and Eukaryotic Cell Cytotoxicity
Published on: November 16, 2016
Azithromycin (zithromax)
1Hilltop Research Centers 6079 N. Fresno #101, Fresno, CA 93710, USA.
Abstract:
Azithromycin (Zithromax), Pfizer, Inc., New York, NY) is a 15-membered-ring macrolide and the first azalide antibiotic. It is distinguished from other macrolides by its rapid and extensive penetration into intracellular and interstitial tissue compartments, accompanied by prolonged tissue and serum half-lives. Azithromycin shares the gram-positive activity of erythromycin but is more potent against gram-negative organisms. For urethritis and cervicitis caused by Chlamydia trachomatis, azithromycin is effective and well tolerated in a single dose of 1 g, a regimen recommended by the CDC. A 5-day dosage regimen is available for the treatment of community-acquired respiratory-tract and skin and skin-structure infections caused by susceptible organisms. Azithromycin provides short-duration, high-compliance, cost-effective regimens that should improve outcomes.
Insights
Azithromycin, an azalide antibiotic, offers rapid tissue penetration and prolonged half-lives. It is effective for Chlamydia infections and respiratory tract infections, providing cost-effective treatment options.
Area of Science:
- Pharmacology
- Microbiology
- Infectious Diseases
Background:
- Azithromycin is a novel azalide antibiotic.
- It exhibits unique pharmacokinetic properties, including rapid tissue penetration and extended half-lives.
- It possesses broad-spectrum activity against Gram-positive and Gram-negative organisms.
Purpose of the Study:
- To review the clinical efficacy and pharmacokinetic profile of azithromycin.
- To highlight its utility in treating specific infections like chlamydial urethritis/cervicitis and community-acquired infections.
- To emphasize its advantages in patient compliance and cost-effectiveness.
Main Methods:
- Review of existing clinical data and pharmacokinetic studies on azithromycin.
- Analysis of treatment outcomes for various infections.
- Comparison with other macrolide antibiotics.
Main Results:
- Azithromycin demonstrates excellent penetration into intracellular and interstitial tissues.
- A single 1g dose is effective for Chlamydia trachomatis infections.
- A 5-day regimen is effective for respiratory tract and skin infections.
- Prolonged serum and tissue half-lives facilitate shorter treatment durations.
Conclusions:
- Azithromycin offers a favorable pharmacokinetic profile and broad-spectrum activity.
- It provides effective and well-tolerated treatment options for STIs and common infections.
- Short-duration, high-compliance, and cost-effective regimens can improve patient outcomes.
More Related Videos
09:17A Robust Pneumonia Model in Immunocompetent Rodents to Evaluate Antibacterial Efficacy against S. pneumoniae, H. influenzae, K. pneumoniae, P. aeruginosa or A. baumannii
Published on: January 2, 2017
06:49Reduced Itraconazole Concentration and Durations Are Successful in Treating Batrachochytrium dendrobatidis Infection in Amphibians
Published on: March 14, 2014
Related Concept Videos
Trichomoniasis
Aryldiazonium Salts to Azo Dyes: Diazo Coupling
Drugs Affecting GI Tract Motility: Antimicrobials as Antidiarrheal Agents
Antiasthma Drugs: Leukotriene Modifiers
Leukotriene modifiers work through two distinct mechanisms:
Antiviral Nucleoside Inhibitors
Inhibitors of Bacterial DNA Synthesis